1. Home
  2. JOURNAL
  3. Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

Download PDF publication
Publication
https://doi.org/10.18632/oncotarget.25324
Domain
Life & Health Sciences
Fellow
Marek Los

Oncotarget. 2018; 9: 24857-24868

Mohammad Hashemi1,2, Gholamreza Bahari2, Jarosław Markowski3, Andrzej Małecki4, Marek J. Łos5,8 and Saeid Ghavami6,7

 

1 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

2 Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

3 ENT Department, School of Medicine, Medical University of Silesia in Katowice, Katowice, Poland

4 Faculty of Physiotherapy, The Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland

5 Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Katowice, Poland

6 Department of Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

7 Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran

8 Centre de Biophysique Moléculaire, CNRS, Rue Charles Sadron, Orleans, France

Abstract

This study was designed to evaluate the relationship between Programmed cell death protein 6 (PDCD6) polymorphisms and cancer susceptibility. The online databases were searched for relevant case-control studies published up to November 2017. Review Manage (RevMan) 5.3 was used to conduct the statistical analysis. The pooled odds ratio (OR) with its 95% confidence interval (CI) was employed to calculate the strength of association. Overall, our results indicate that PDCD6 rs3756712 T>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70–0.96, p = 0.01, TG vs TT; OR = 0.53, 95%CI = 0.39-0.72, p < 0.0001, GG vs TT), dominant (OR = 0.76, 95%CI = 0.66-0.89, p = 0.0004, TG+GG vs TT), recessive (OR = 0.57, 95%CI = 0.43-0.78, p = 0.0003, GG vs TT+TG), and allele (OR = 0.76, 95%CI = 0.67–0.86, p < 0.00001, G vs T) genetic model. The finding did not support an association between rs4957014 T>G polymorphism of PDCD6, and different cancers risk.

Keywords

PDCD6
Meta-analysis
Cancer
Risk
Endometrial Cancer
Published by

Oncotarget